KUALA LUMPUR, Aug 25 -- Grafana Labs, the company behind the world’s most ubiquitous open and composable operational dashboards, has announced a US$220 million Series C investment round, co-led by new investors Sequoia Capital and Coatue, with participation from existing investors Lightspeed Venture Partners, Lead Edge Capital, and GIC. (US$1 = RM4.211)
As part of the funding, Carl Eschenbach, partner at Sequoia and former President and COO at VMware, and David Schneider, general partner at Coatue and former President at ServiceNow, will join the company’s board of directors.
The ‘actually useful’ free forever tier of Grafana Cloud provides the industry’s most generous no-cost observability stack, and with the funding round, Grafana Labs is adding 50GB of traces to the 50GB of logs, 10,000 series of Prometheus metrics, and 3 Grafana dashboard users that come with the free offering.
Both Grafana Cloud and the on-premises Grafana Enterprise Stack offering include access to free and commercial plugins, such as Elasticsearch, Jira, Datadog, Splunk, AppDynamics, Oracle, MongoDB, Snowflake, ServiceNow, and more.
“It’s been an incredible year at Grafana Labs, highlighted by the rapid adoption of Grafana Cloud, the growth of our Loki logs and Prometheus metrics offerings, the introduction of Tempo 1.0 for tracing, and the continued development of the Grafana frontend,” said Grafana Labs co-founder and CEO, Raj Dutt in a statement.
“This new investment of capital, as well as the addition of two highly experienced technology executives to our board, will focus us on accelerating product development to support our community’s and customers' success.”
Eschenbach said: “We’re eager to partner with Grafana Labs and look forward to working with Raj and team to continue building world-class observability products.”
Grafana Labs has doubled its headcount since the beginning of the year, with nearly 500 Grafanistas working remotely in more than 40 different countries.
For more information, visit www.grafana.com.
-- BERNAMA
No comments:
Post a Comment